Molecular basis and management of gastrointestinal stromal tumors

doi:10.3748/wjg.v16.i22.2726

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 22

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4181)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

382

HTML

3420

Figures (1-2)

171

Tables (1-4)

208

Sum=4181

Jun 14, 2010 (publication date) through Jul 26, 2024

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jun 14, 2010; 16(22): 2726-2734
Published online Jun 14, 2010. doi: 10.3748/wjg.v16.i22.2726

Table 2 Adjuvant and neoadjuvant trials of imatinib in patients with GISTs

Trial	Accrual	Eligibility	Therapy (n)	End points
Phase II study of adjuvant imatinib mesylate in patients with completely resected high-risk primary GIST (ACOSOG-Z9000)	Closed	Diameter > 10 cm or tumor rupture or multifocal	Imatinib 400 mg daily for 1 year (107)	2-year OS: 97%, 2-year RFS: 73%[33]
Phase III randomized study of adjuvant imatinib mesylate in patients with resected primary GIST (ACOSOG-Z9001)	Closed	Diameter > 3 cm	Imatinib 400 mg daily for 1 year (359)	1-year RFS: 98%[36]
	Closed	Diameter > 3 cm	Placebo (354)	1-year RFS: 83%
EORTC soft tissue and bone sarcoma group (EORTC-62024) randomized phase III trial	Closed	Diameter > 5 cm or mitotic rate > 5/50 HPF	Imatinib 400 mg daily for 2 years	Primary: OS
	Closed	Diameter > 5 cm or mitotic rate > 5/50 HPF	Observation (Total projected 750)	Secondary: RFS and safety
Scandinavian sarcoma group trial SSGXVIII	Closed	Diameter > 10 cm or mitotic rate > 10/50 HPF or > 5 cm and > 5/50 HPF or tumor rupture	Imatinib 400 mg daily for 36 mo	Primary: RFS
Scandinavian sarcoma group trial SSGXVIII	Closed		Imatinib 400 mg daily for 12 mo (Total projected 280)	Secondary: OS, safety
Phase II study of neoadjuvant and adjuvant imatinib mesylate in patients with primary or recurrent potentially resectable malignant GIST (RTOG-S0132)	Closed	Locally advanced or metastatic/recurrent	Imatinib 600 mg daily for 6-8 wk followed by debulking/resection (52)	2-year PFS: 80%, objective response rate: 6%, R0 resection in 65%[39]
Five year adjuvant imatinib mesylate in GIST (Phase II)	Open	Diameter > 2 cm and mitotic rate > 5/50 HPF or non-gastric GIST > 5 cm	Imatinib 400 mg daily for 5 years (Projected 133)	Primary: Time to recurrence
Five year adjuvant imatinib mesylate in GIST (Phase II)	Open		Imatinib 400 mg daily for 5 years (Projected 133)	Secondary: Safety
Phase II study of neoadjuvant imatinib mesylate in patients with locally advanced gastrointestinal stromal tumor (Germany/Austria)	Open	Locally advanced, KIT expressing, histologically confirmed GIST	Imatinib 400 mg daily/BID (Projected 40)	Primary: ORR Secondary: R0-resectability and organ-preserving resectability

OS: Overall survival; RFS: Relapse-free survival; PFS: Progression-free survival.

Citation: Bayraktar UD, Bayraktar S, Rocha-Lima CM. Molecular basis and management of gastrointestinal stromal tumors. World J Gastroenterol 2010; 16(22): 2726-2734
URL: https://www.wjgnet.com/1007-9327/full/v16/i22/2726.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i22.2726